Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for August 2012
August 1, 2012
- Cleveland BioLabs Announces Publication of Studies Identifying Biomarkers of CBLB502's Efficacy as a Radiation Countermeasure
- Pfizer Announces Positive Top-Line Results From The ORAL Start Phase 3 Study Of Tofacitinib In Rheumatoid Arthritis
- Isis And Collaborators Alleviate Disease In Animal Models Of Myotonic Dystrophy
August 2, 2012
- DBV Technologies initiates VIPES phase IIb clinical study, the first global trial ever in desensitization of peanut-allergic children and adults
- Cannabis Science Presents at World AIDS Institute Treatment Horizons Satellite Symposium during AIDS 2012 in Washington DC
- Nymox Reports Positive Results From Combined Statistical Analysis of Long Term Follow-Up Studies of BPH Drug
- Test Results Show Unprecedented Achievement for Marburg Drug Candidate
- Array BioPharma's ARRY-797 Meets Primary Endpoint in Clinical Proof of Concept Trial in Osteoarthritis Patients Whose Pain is Poorly Controlled by NSAIDs
- Spectrum Pharmaceuticals Announces Publication in the Journal of Clinical Oncology of Encouraging ZEVALIN Data in Patients with Mantel-Cell Lymphoma
August 3, 2012
- Results For Phase 2b Trial Of Unique Investigational Cell-Based Therapy In Venous Leg Ulcers Published In The Lancet
- Study Shows Toviaz Is Effective In Reducing Urge Urinary Incontinence In Patients With Overactive Bladder After Suboptimal Response To Detrol LA
- Target for potent first-strike influenza drugs identified
August 6, 2012
- Rexahn Pharmaceuticals Completes Exploratory Phase I Clinical Study of RX-3117
- TWi Pharmaceuticals Announces Positive Phase IIb Clinical Trial Results of AC-201 in Patients with Type 2 Diabetes.
- Positive Clinical Trial Results for Immunovaccine?s DPX-0907 Published in Journal of Translational Medicine
- Alnylam Presents New Data from its Conjugate Delivery Platform, Enabling Subcutaneous Administration of RNAi Therapeutics with Wide Therapeutic Index
August 7, 2012
- Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures
- Agennix Reports Results of FORTIS-M Phase III Trial With Talactoferrin Alfa in Non-Small Cell Lung Cancer
August 8, 2012
- BTG Announces Data from Phase IIb Study of AZD9773
- Achillion Announces Positive SVR4 Results From Phase 2 Study of Sovaprevir (Formerly ACH-1625) and Advancement of ACH-3102
- Agenus Announces Publication of Key Data Showing Antitumor Activity of Prophage Vaccine (HSPPC-96) in Clinical Cancer Research
- No difference in death rates among patients exposed to common rheumatoid arthritis drugs
August 10, 2012
- Genentech Study Showed That Adding Avastin to Radiation and Chemotherapy Significantly Extended the Time People with an Aggressive Form of Brain Cancer Lived without Their Disease Worsening
- Nanomaterials help heart to heal: NCKU study
- MultiCell Technologies Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in vitro Models
- Pfizer Reports Results From Phase 3 Study Of Torisel (temsirolimus) In Combination With Bevacizumab In Advanced Renal Cell Carcinoma (RCC)
- Data From Phase I Trial of ICT-107 Accepted for Publication in Prestigious Medical Journal, Cancer Immunology, Immunotherapy
- Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
- Genkyotex's Lead NOX Inhibitor GKT137831 Demonstrates Activity in Models of Liver Fibrosis
August 11, 2012
August 13, 2012
- Acorda Therapeutics Announces Top Line Results of Post-Marketing Commitment Study Exploring 5 mg Dose of Dalfampridine-ER
- NanoViricides Reports That Oral Administration of FluCide, its Anti-Influenza Drug Candidate Was Effective In Animal Model
- Aeterna Zentaris to Present Preclinical Data for PI3K/Erk 1/2 Inhibitor, AEZS-136, at ACS National Meeting
- Study Suggests Patients Should Be Screened Before Receiving Vemurafenib
- Cook Medical's Ongoing Zilver PTX Trial Data Show Higher Freedom From Target Lesion Revascularization (TLR) Rates Compared to Angioplasty and Bare Metal Stenting After Three Years
- Senesco Announces Highly Statistically Significant Tumor Growth Inhibition by a Combination of Lenalidomide and SNS01-T in Cancer Model
August 14, 2012
- Tonix Pharmaceuticals Reports That Sublingual Formulation of Fibromyalgia Drug Reduces Production of a Psychoactive Metabolite, Improving Suitability for Long-Term, Chronic Treatment
- Proteostasis Therapeutics Presents Data at Multiple Scientific Conferences Highlighting Novel Approach to Neurodegenerative Diseases and Cystic Fibrosis
August 16, 2012
- Phase III Results Published in NEJM Show Ocriplasmin could be First Pharmacological Eye Treatment for Vitreomacular Adhesion Patients
- New England Journal of Medicine Publishes Results from Phase 3 AFFIRM Trial of Enzalutamide
- Tonix Pharmaceuticals CEO Dr. Seth Lederman Describes Potential Treatment for Fibromyalgia, Post-Traumatic Stress Disorder and Traumatic Brain Injury
August 17, 2012
- Evolva?s EV-077 achieved objectives in first group of patients in Phase IIa trial
- Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
- Turmeric Spices Up Virus Study
- University of Miami study finds RBAC to possess promising immunomodulating effects with respect to natural killer cell and cytokine activity
- Senesco Announces that SNS01-T Showed Good Tolerability and Stable Disease in Newly Completed First Cohort of Phase 1b/2a Multiple Myeloma Trial
August 20, 2012
- NanoViricides Reports That Oral Administration of FluCide Anti-Influenza Drug Candidates Led to Survival Improvements Comparable to IV Administration and Was Far Superior to Oseltamivir, in a Highly Lethal Animal Model
- ELIQUIS (apixaban) Data Analyses To Be Presented At European Society of Cardiology Congress 2012
- Making Sense Out of the Biological Matrix of Bipolar Disorder
- Epilepsia Publishes Results From Two Studies Of Eisai's Perampanel
- Ocular Therapeutix Commences Pilot Phase II Travoprost Punctum Plug Study for the Treatment of Glaucoma
August 21, 2012
- Study Examines Risk of Heart Attack Associated With Various Psoriasis Treatments
- Hitting Cancer from All Sides
August 22, 2012
- Alnylam and Collaborators Publish New Pre-clinical Results on Ex Vivo Applications of RNAi to Enhance Dendritic Cell Vaccines for Cancer
- Symphogen Publishes Final Rozrolimupab (SYM001) Phase 2 Trial Results in ITP in BLOOD Journal
- Inavir prevention study achieves primary endpoint
August 23, 2012
August 24, 2012
- Eli Lilly and Company Announces Top-Line Results on Solanezumab Phase 3 Clinical Trials in Patients with Alzheimer's Disease
- MediciNova Announces Positive Preliminary Results From a Multi-Day, Repeat-Dose Clinical Trial With MN-221 in Chronic Obstructive Pulmonary Disease Patients
- Use of Newer-Generation Drug-Releasing Stent Results in Lower Rate of Adverse Cardiac Events For Heart Attack Patients
August 27, 2012
- Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure
- New Novartis Phase II data Show LCZ696 May Provide Clinical Benefits in Patients with a Difficult-to-Treat Form of Heart Failure
- ImmunoGen, Inc. Announces Trastuzumab Emtansine (T-DM1) Significantly Improved Survival in the EMILIA Phase III Trial
- New Data from Phase III EMILIA Study Showed Genentech's Trastuzumab Emtansine (T-DM1) Significantly Improved Survival of People With HER2-Positive Metastatic Breast Cancer
- Webcast Alert: Isis Pharmaceuticals Hosts Dr. Klaus Parhofer to Review KYNAMRO Data Presented at the European Society of Cardiology Congress 2012
- NanoViricides Reports that Oral Administration of FluCide Anti-Influenza Drug Candidates Caused Lung Viral Load Decrease Comparable to IV Administration and Far Superior to Oseltamivir, in a Highly Lethal Animal Model
- Auxilium Pharmaceuticals Announces Additional Phase III XIAFLEX Data To Be Presented at SMSNA Meeting
- Pulmatrix Announces Presentations at European Respiratory Society Annual Congress for Lead Inhaled iCALM Drug Candidate, PUR118
- Lack of Sleep Found to be a New Risk Factor for Aggressive Breast Cancers
- InterMune Announces Presentations of New Research in IPF at ERS
August 28, 2012
- Acorda Therapeutics Announces GGF2 Preclinical Data on Treatment of Erectile Dysfunction
- Rexahn Pharmaceuticals Announces Positive Top-line Phase IIa Data for Archexin in Patients with Metastatic Pancreatic Cancer
- Spinifex Announces Positive Phase 2 Results for EMA401 in Postherpetic Neuralgia
- Resverlogix's BET Protein Inhibitor RVX-208 Meets Primary Endpoint in SUSTAIN Clinical Trial in Patients With High Risk Cardiovascular Disease
- Study Reviews Discontinuation of LABA Therapy in Patients with Asthma
- Study Compares Cardiovascular Events, Stroke in Patients Prescribed Beta-Blockers for Hypertension
- Bolder BioTechnology Announces Publication of Data Demonstrating Utility of the Company's Long-Acting IL-11 Analog to Prevent Renal Ischemia Reperfusion Injury
- Society for Cardiovascular Angiography and Interventions (SCAI) Statement on FAME 2 (FRACTIONAL FLOW RESERVE VERSUS ANGIOGRAPHY FOR MULTI-VESSEL EVALUATION 2), Presented at the European Society of Cardiology 2012 Congress and Published in The New England Journal of Medicine
August 29, 2012
- Durata Therapeutics Announces Five Abstracts Concerning Dalbavancin and Management of abSSTI at ICAAC 2012
- Evolva reports additional Phase IIa data on EV-077
- POZEN Announces PA32540 Provides Superior Antiplatlet Effects over a Standard of Care Regimen in a Phase 1 Study (?Co-Rx?)
- Protalex, Inc. Completes Analysis of Data from Phase 1b Dose Escalation Study of PRTX-100 in Patients with Active Rheumatoid Arthritis
- Amarin Announces Additional Publication of MARINE Phase 3 Clinical Trial Results in the Journal of Clinical Lipidology
- RegeneRx's T?4 Promotes Recovery of Peripheral Neuropathy in Type II Diabetic Mice
August 30, 2012
- Soligenix Announces Positive Phase 1B Clinical Results with RiVax, its Vaccine Against Ricin Toxin Exposure
- Novartis QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients, Filing in EU and Japan by End of Year
- Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
- ARMGO Pharma, Inc. announces data which supports its Rycal program as a novel approach for the treatment of stress-induced cognitive disorders
August 31, 2012
- Sophiris' Drug for Benign Prostatic Hyperplasia was Well Tolerated Using the Preferred Transrectal Route of Administration
- Spiriva HandiHaler (tiotropium bromide inhalation powder) and COPD Data to be Presented at the 2012 European Respiratory Society (ERS) Congress
- BG Medicine, Inc. Announces Publication of Important Galectin-3 Study Designed to Identify Adults in General Population at Risk for Heart Failure
- Prana's Parkinson's drug meets Michael J. Fox Foundation development milestone
- NeurogesX' NGX-1998 Well-Tolerated Treatment Demonstrated Clear Dose-Response in Patients
- Aspirin-Clopidogrel No Better Than Aspirin Alone for Patients With Lacunar Stroke
